These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 7963492)

  • 1. Myricerone caffeoyl ester (50-235) is a non-peptide antagonist selective for human ETA receptors.
    Maguire JJ; Bacon CR; Fujimoto M; Davenport AP
    J Hypertens; 1994 Jun; 12(6):675-80. PubMed ID: 7963492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological properties of J-104132 (L-753,037), a potent, orally active, mixed ETA/ETB endothelin receptor antagonist.
    Nishikibe M; Ohta H; Okada M; Ishikawa K; Hayama T; Fukuroda T; Noguchi K; Saito M; Kanoh T; Ozaki S; Kamei T; Hara K; William D; Kivlighn S; Krause S; Gabel R; Zingaro G; Nolan N; O'Brien J; Clayton F; Lynch J; Pettibone D; Siegl P
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1262-70. PubMed ID: 10336515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ETA receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro.
    Maguire JJ; Davenport AP
    Br J Pharmacol; 1995 May; 115(1):191-7. PubMed ID: 7647976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Affinity and selectivity of PD156707, a novel nonpeptide endothelin antagonist, for human ET(A) and ET(B) receptors.
    Maguire JJ; Kuc RE; Davenport AP
    J Pharmacol Exp Ther; 1997 Feb; 280(2):1102-8. PubMed ID: 9023329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonpeptide endothelin receptor antagonists. VI: Pharmacological characterization of SB 217242, a potent and highly bioavailable endothelin receptor antagonist.
    Ohlstein EH; Nambi P; Lago A; Hay DW; Beck G; Fong KL; Eddy EP; Smith P; Ellens H; Elliott JD
    J Pharmacol Exp Ther; 1996 Feb; 276(2):609-15. PubMed ID: 8632328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endothelin receptor subtypes and their functional relevance in human small coronary arteries.
    Pierre LN; Davenport AP
    Br J Pharmacol; 1998 Jun; 124(3):499-506. PubMed ID: 9647474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of peptide and nonpeptide antagonists in human kidney.
    Kuc RE; Karet FE; Davenport AP
    J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S373-5. PubMed ID: 8587419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potency of PD155080, an orally active ETA receptor antagonist, determined for human endothelin receptors.
    Maguire JJ; Kuc RE; Doherty AM; Davenport AP
    J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S362-4. PubMed ID: 8587415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonpeptide endothelin receptor antagonists. XI. Pharmacological characterization of SB 234551, a high-affinity and selective nonpeptide ETA receptor antagonist.
    Ohlstein EH; Nambi P; Hay DW; Gellai M; Brooks DP; Luengo J; Xiang JN; Elliott JD
    J Pharmacol Exp Ther; 1998 Aug; 286(2):650-6. PubMed ID: 9694916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelin ETA and ETB mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ETA sub-type.
    Davenport AP; O'Reilly G; Kuc RE
    Br J Pharmacol; 1995 Mar; 114(6):1110-6. PubMed ID: 7620699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regional variations in ETA/ETB binding sites in human coronary vasculature.
    Dashwood MR; Timm M; Kaski JC
    J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S351-4. PubMed ID: 8587412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological profile of ZD1611, a novel, orally active endothelin ETA receptor antagonist.
    Wilson C; Hunt SJ; Tang E; Wright N; Kelly E; Palmer S; Heys C; Mellor S; James R; Bialecki R
    J Pharmacol Exp Ther; 1999 Sep; 290(3):1085-91. PubMed ID: 10454481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacology of two novel mixed ETA/ETB receptor antagonists, BQ-928 and 238, in the carotid and pulmonary arteries and the perfused kidney of the rabbit.
    Maurice MC; Gratton JP; D'Orléans-Juste P
    Br J Pharmacol; 1997 Jan; 120(2):319-25. PubMed ID: 9117126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receptor binding and antagonist properties of a novel endothelin receptor antagonist, TAK-044 [cyclo[D-alpha-aspartyl-3-[(4-phenylpiperazin-1-yl) carbonyl]-L-alanyl-L-alpha-aspartyl-D-2-(2-thienyl) glycyl-L-leucyl-D-tryptophyl]disodium salt], in human endothelinA and endothelinB receptors.
    Masuda Y; Sugo T; Kikuchi T; Kawata A; Satoh M; Fujisawa Y; Itoh Y; Wakimasu M; Ohtaki T
    J Pharmacol Exp Ther; 1996 Nov; 279(2):675-85. PubMed ID: 8930171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonpeptide endothelin receptor antagonists. VII: Binding characteristics of [3H]SB 209670, a novel nonpeptide antagonist of endothelin receptors.
    Nambi P; Pullen M; Wu HL; Lee D; Saunders D; Heys R; Aiyar N; Leber J; Elliott J; Brooks D; Ohlstein E; Ruffolo R
    J Pharmacol Exp Ther; 1996 Jun; 277(3):1567-71. PubMed ID: 8667224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of [125I]-PD164333, an ETA selective non-peptide radiolabelled antagonist, in normal and diseased human tissues.
    Davenport AP; Kuc RE; Ashby MJ; Patt WC; Doherty AM
    Br J Pharmacol; 1998 Jan; 123(2):223-30. PubMed ID: 9489609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological profile of T-0201, a highly potent and orally active endothelin receptor antagonist.
    Hoshino T; Yamauchi R; Kikkawa K; Yabana H; Murata S
    J Pharmacol Exp Ther; 1998 Aug; 286(2):643-9. PubMed ID: 9694915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the contractile effects and binding kinetics of endothelin-1 and sarafotoxin S6b in rat isolated renal artery.
    Devadason PS; Henry PJ
    Br J Pharmacol; 1997 May; 121(2):253-63. PubMed ID: 9154335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist.
    Opgenorth TJ; Adler AL; Calzadilla SV; Chiou WJ; Dayton BD; Dixon DB; Gehrke LJ; Hernandez L; Magnuson SR; Marsh KC; Novosad EI; Von Geldern TW; Wessale JL; Winn M; Wu-Wong JR
    J Pharmacol Exp Ther; 1996 Feb; 276(2):473-81. PubMed ID: 8632312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ETA receptors predominate in the human vasculature and mediate constriction.
    Davenport AP; Kuc RE; Maguire JJ; Harland SP
    J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S265-7. PubMed ID: 8587384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.